VolitionRx Limited
VNRXStock
$1.16−90.72%52W
Market Cap$15.30M
P/E—
Div yield—
Beta1.14
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-85.75%
Price vs S&P 500 (4W)-11.41%
VGM Score50.06
Market Capitalization$15.30M
Earnings Surprise History
Q1 26-0.97est. -0.73
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
3.91
4.00
4.00
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VNRXVolitionRx Limited | C | A | F | $1.16 |
| IDXXIdexx Laboratories Inc | D | B | C | $576.07 |
| LNTHLantheus Holdings, Inc | C | B | B | $105.11 |
| CLDXCelldex Therapeutics, Inc | F | F | B | $35.40 |
| NEOGNeogen Corp | C | C | B | $10.33 |
| NTLAIntellia Therapeutics, Inc | D | C | C | $11.86 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | F | $9.60 |
| QDELQuidelOrtho Corporation Common Stock | C | C | C | $18.24 |
| ACHVAchieve Life Sciences, Inc. | F | F | A | $5.96 |
| MYGNMyriad Genetics Inc | C | C | B | $6.19 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $5.32 |
About
VolitionRX Ltd develops blood-based diagnostic tests using its proprietary Nucleosomics platform to identify disease markers from circulating nucleosomes. The company's tests provide simple, cost-effective alternatives for diagnosing and monitoring cancers, sepsis, COVID-19, and other serious diseases. VolitionRX operates in both human and veterinary diagnostics, targeting underserved markets with accessible diagnostic solutions.